SCHEMBL23609124

SCHEMBL23609124

CCOC(=O)C1CC(C(F)F)=NNC1=O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.56
LMNA P02545 1/20 0.54
MAPT P10636 3/20 0.40
HSD17B10 Q99714 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPK1 P28482 1/20 0.33
TLR4 O00206 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19463937 0.81 RAB9A (0.63) RAB9ALMNAMAPTHSD17B10ALDH1A1
SCHEMBL20338306 0.78 RAB9A (0.60) RAB9ALMNAMAPTHSD17B10ALDH1A1
SCHEMBL19463838 0.76 RAB9A (0.57) RAB9ALMNAMAPTHSD17B10ALDH1A1
SCHEMBL6014875 0.72 RAB9A (1.00) RAB9ALMNAMAPTHSD17B10ALDH1A1
SCHEMBL28802880 0.70 LMNA (1.00) RAB9ALMNAMAPTALDH1A1MEN1
SCHEMBL7277682 0.70 LMNA (0.78) RAB9ALMNAMAPTHSD17B10ALDH1A1
SCHEMBL1322979 0.69 RAB9A (0.49) RAB9ALMNAMAPTHSD17B10ALDH1A1
SCHEMBL25439588 0.69 RAB9A (0.49) RAB9ALMNAMAPTHSD17B10ALDH1A1
SCHEMBL10405813 0.68 RAB9A (0.48) RAB9ALMNAMAPTHSD17B10ALDH1A1
SCHEMBL3196831 0.66 ALDH1A1 (0.56) RAB9ALMNAMAPTHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114945571-B Cyclic compounds and methods of use thereof 薛定谔公司 2025-02-25 CN disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
EP-4081526-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME Schrödinger, Inc. (US) 2022-11-02 EP disclosed
CN-114945571-A Cyclic compounds and methods of use thereof 薛定谔公司 2022-08-26 CN disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 WO disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME MALT1, FKBP1B, FKBP1A RAB9A 1554/4885LMNA 4221/4885MAPT 3951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.